Showing results (1221-1230 of 1,669) with videos related to

Sort By:
Pageof 167
Archives of Toxicology|March 13, 2003
Nasal midazolam as a novel anticonvulsive treatment against organophosphate-induced seizure activity in the guinea pigE Gilat, M Goldman, E Lahat, et al.
Leukemia|August 1, 1993
Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: an updated meeting report and reviewM N Potter, N C Cross, J J van Dongen, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2011
Scale-up and continuation of antiretroviral therapy in South African treatment programs, 2005-2009Jeffrey D Klausner, Celicia Serenata, Heidi O'Bra, et al.
Bone Marrow Transplantation|April 10, 1999
Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled studyS M Kelsey, J M Goldman, S McCann, et al.
Haematologica|June 28, 2000
Collection of Ph-negative progenitor cells from interferon responsive patients with chronic myeloid leukemia: effect of granulocyte-colony-stimulating factor mobilizationE Olavarria, S Parker, C Craddock, et al.
Kidney International|January 1, 1996
Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro hemodialysisC Tielemans, C Husson, T Schurmans, et al.
Kidney International|November 1, 1992
Procoagulant effect of the OKT3 monoclonal antibody: involvement of tumor necrosis factorO Pradier, A Marchant, D Abramowicz, et al.
Lancet (London, England)|March 28, 1992
Induction of thromboses within renal grafts by high-dose prophylactic OKT3D Abramowicz, O Pradier, A Marchant, et al.
Blood|August 8, 1998
The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biologyF Dazzi, D Capelli, R Hasserjian, et al.
Cancer|March 24, 2005
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinibDavid Marin, Jaspal S Kaeda, Catharina Andreasson, et al.
Pageof 167